ZVRA

Business Context and Reporting Period

Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage biopharmaceutical company focused on rare diseases. This Form 10-Q covers the quarterly period ended September 30, 2025. The company's portfolio includes FDA-approved products MIPLYFFA (for Niemann-Pick disease type C) and OLPRUVA (for urea cycle disorders), alongside clinical-stage candidates celiprolol and KP1077.

Key Financial Metrics

Note: 9M 2025 Net Income includes a non-recurring gain on the sale of a Priority Review Voucher (PRV) of $148.3 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased significantly to $26.1 million in Q3 2025 from $3.7 million in Q3 2024, driven primarily by $22.4 million in sales of MIPLYFFA.
• Profitability Shift: The company reported a net loss of $0.5 million in Q3 2025, a substantial improvement from the $33.2 million loss in Q3 2024. For the nine months ended September 30, 2025, the company reported net income of $71.1 million compared to a net loss of $69.8 million in the prior year period.
• Impairment Charges: A non-cash impairment charge of $58.7 million was recorded in Q2 2025 (included in 9M results) related to the OLPRUVA intangible asset group due to revised commercial expectations. No impairment was recorded in the prior year.
• Inventory Write-downs: Inventory obsolescence charges totaled $11.7 million for the nine months ended September 30, 2025, compared to $5.2 million in the prior year period.
• PRV Sale: The company consummated the sale of a Priority Review Voucher on April 1, 2025, generating net proceeds of $148.3 million, recorded as a gain in the 9M 2025 results.

Guidance, Outlook, and Risks

• Liquidity: As of September 30, 2025, the company held $230.4 million in cash, cash equivalents, and investments. Management believes these resources are sufficient to fund operations for at least the next twelve months.
• Commercial Outlook: MIPLYFFA is commercially available in the U.S. and has received orphan designation in Europe, with a Marketing Authorization Application (MAA) submitted in July 2025. OLPRUVA commercialization continues, though recent impairment reflects lower-than-expected cash flow projections.
• Legal Proceedings: The company is engaged in litigation with Commave Therapeutics regarding the interpretation of the AZSTARYS License Agreement. The case is in the discovery phase, and while the agreement remains in effect, the outcome is uncertain and could impact future royalty revenues.
• Risk Factors: Key risks include the ability to raise additional capital, regulatory approval timelines for pipeline candidates (celiprolol, KP1077), and potential impacts from healthcare reform legislation (e.g., the "One Big Beautiful Bill Act" enacted in July 2025).

Investor Verification Checklist

• PRV Gain Sustainability: Verify that the $148.3 million gain from the PRV sale is a one-time event and does not reflect recurring operational profitability.
• OLPRUVA Impairment: Review the assumptions used in the $58.7 million impairment charge to understand the revised commercial trajectory for OLPRUVA.
• Debt Covenants: Confirm compliance with the $20 million minimum cash balance covenant and minimum net product sales requirements under the $100 million term loan facility.
• Legal Exposure: Monitor the status of the AZSTARYS litigation with Commave, as a negative outcome could affect royalty streams and require significant legal expenditures.
• Inventory Valuation: Assess the $11.7 million inventory obsolescence charge and the remaining inventory balance to gauge potential future write-downs.